l carnitine with tirzepatide levocarnitine: complete guide to the compounded combination CarniTide™ & CarniSema™: Enhanced Weight

Currently, the first-generation drug pramlintide is used as an adjunct to insulin therapy in the treatment of T2D but is not approved for the treatment of obesity

The strongest effects accumulate at higher dose levels (10-15mg) as tirzepatide reaches its full GIP-plus-GLP-1 potency

Eryptosis in peritoneal dialysis-related peritonitis: the potential role of inflammation in mediating the increase in eryptosis in PD

#ASAIO To view or add a comment, sign in **Drug of Choice in Cardiology Quick Clinical Reference** This chart highlights the commonly accepted *drugs of choice* for major cardiovascular conditions, serving as a quick revision guide for students and healthcare professionals

doi: 10.3797/scipharm.0912-18